CTOs on the Move

Immunocellular Therapeutics (Fka: Optical Molecu

www.imuc.com

 
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imuc.com
  • 21900 Burbank Blvd Fl 3
    Woodland Hills, CA USA 91367
  • Phone: 818.992.2907

Executives

Name Title Contact Details

Similar Companies

Culture Biosciences

Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.

Formycon

Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.

Diagnose Early

Diagnose Early Corp is a biotechnology company that specializes in non-invasive breath biopsy health data platform powered by AI. They are commercializing diagnostics for cancer, neurological, and infectious diseases, and are in clinical trials at Stan...

Bannerbio Nutraceutiocals Inc

Bannerbio Nutraceutiocals Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMarin

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company`s product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.